Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A

Hemophilia News Today

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL